Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential

3. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Number of Hedge Fund Holders as of Q4: 40

Tao Capital’s Equity Stake: $40.28 Million

Upside Potential as of May 8: 41.96%

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company dedicated to developing novel therapies for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease with significant unmet medical need. The company’s flagship product, Rezdiffra, has shown strong commercial performance since its FDA approval in March 2024, becoming the first approved therapy for F2-F3 MASH in the U.S.

In the first quarter of 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported net revenues of $137.3 million, marking significant growth as no product sales were recognized during the same period last year. This revenue increase was primarily driven by Rezdiffra’s market penetration, which saw more than 17,000 patients on the treatment as of March 31, 2025. Rezdiffra generated $137 million in net sales during Q1, reflecting a 33% sequential increase compared to the previous quarter, highlighting its rapid adoption in the MASH treatment landscape.

Despite the strong revenue performance, the company’s operating expenses also rose, totaling $216.6 million in Q1 2025 compared to $152.0 million in the prior-year period. This increase reflects ongoing commercialization efforts and the expansion of Rezdiffra’s reach within the market. As of March 31, 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) maintained a strong liquidity position, with cash, cash equivalents, and marketable securities amounting to $848.1 million.

Madrigal’s continued focus on addressing a high unmet need within liver disease, coupled with Rezdiffra’s impressive commercial uptake, positions the company well for long-term growth. The increase in patient numbers and sustained revenue trajectory underline the drug’s market potential, reinforcing Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)’s strategic position within the biopharmaceutical sector.